Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

Mitochondria-Targeted Drug Development 2022 Boston US

From Bioblast


MitoGlobal         MitoGlobal Societies         MiPsociety         Asia Society for Mitochondrial Research and Medicine         MitoGlobal Events         MitoGlobal first



Mitochondria-Targeted Drug Development 2022 Boston US

Publications in the MiPMap
Mitochondria Targeted Therapeutics
Boston, MA US, 2022 Feb 22-24. 2nd Annual Mitochondria-Targeted Drug Development - Overcome the Challenge of Treating Unmet Medical Needs Caused by Mitochondrial Dysfunction

» Conference website

hansonwade (2022-02-22) MitoGlobal

Abstract: 2nd Annual Mitochondria-Targeted Drug Development, Boston MA, US, 2022.


General information

We are happy to announce that the Mitochondria-Targeted Drug Development Summit, focused on the pursuit for novel effective therapies for mitochondrial disorders/dysfunction, will be delivered in-person, for its 2nd edition.
Incorporating insights from leading academics and pioneering biotech, this forum will specifically focus on targeting mitochondrial dysfunction to develop therapies for chronic diseases caused by mitochondrial DNA mutation/nuclear DNA mutations, muscle dystrophy diseases/muscle loss, metabolic disorders, neurodegenerative disease, and conditions linked to oxidative damage.
From basic research to the clinic, this year’s meeting will examine novel preclinical animal modelling solutions specifically targeting mitochondria, deliver an update on the current leading clinical trials showcasing mitochondrial transfer, mutations, metabolism, quality control, biogenesis, and peroxidation/ oxidation, along with dedicated sessions on the significance on informatics and data sharing for precision medicine.
Join 80+ leading experts as they navigate common challenges and opportunities for treating unmet medical needs caused by mitochondrial dysfunction. :::: :::: :::: Mitobridge/Astellas, Minovia Therapeutics, Abliva, GenSight Biologics, Stealth Biotherapeutics and many more will unite drive to better understand how to create effective and scalable mitochondrial therapies.


Download the brochure here

Program

The program is available here

Registration

Register here
Early bird & Team Discounts Available until December, 17

Organizer

Hanson Wade
Mail: [email protected]
https://hansonwade.com/

Speaker

See the full list of speakers here
  • Reenie McCarthy, CEO, Stealth BioTherapeutics Inc.
  • Gino Cortopassi, CEO, Ixchel Pharma
  • Selvaraj Nataraja, Senior Director, Translational Research, Mitobridge
  • Matthew Klein, Chief Development Officer, PTC Therapeutics
  • Keshav Singh, Joy & Bill Harbert Endowed Chair & Professor/Scientific Founder & Chief Scientific Officer, University of Alabama, Birmingham/Yuva Biosciences
  • David Schaaf, Vice President, US Medical Affairs, Senior Medical Officer, Zogenix
  • Ellen Donnelly, Chief Executive Officer, Abliva AB
  • Bärbel (Barb) Rohrer, Ph.D., Co-Founder & Chief Scientific Officer, MitoChem Therapeutics
  • Dan DiPietro, Founding Partner, Aceras Bio
  • Benedict Albensi, Scientific Advisor, Mitrix Bio, Nova Southeastern University
  • Christopher Missling, President & CEO, Anavex Life Sciences Corp.
  • Rishi Rakhit, Director, Translational Medicine, Mitokinin Inc.
  • David Marcinek, Professor of Radiology, Adjunct of Bioengineering and Laboratory Medicine and Pathology, University of Washington Medical School
  • Gregory J. Flesher, President & CEO, Reneo Pharmaceuticals
  • Michael Fossel, President & Founder, Telocyte
  • Jonah Sinick, Chief Executive Officer, Equator Therapeutics
  • Penelope Andreux, Head of Drug Discovery, Amazentis/Vandria
  • Maxim Skulachev, Chief Scientific Officer, Mitotech S.A.
  • Hazel Szeto, Co-Founder & Director/Scientific Founder, Improving Global Health, Inc./Stealth BioTherapeutics
  • Magali Taiel, Chief Medical Officer, GenSight Biologics
  • Victor Shengkan Jin, Founder, Mito BioPharma
  • Alexander Schueller, Founder & Chief Executive Officer, Cellvie AG
  • Daria Mochly-Rosen, The George D Professor, Translational Medicine, Professor, Dept Chemical & Systems Biology/Founder & Co-director, Stanford University, School of Medicine/SPARK, Stanford
  • Natalie Yivgi-Ohana, Co-Founder & Chief Executive Officer, Minovia Therapeutics Ltd.
  • Joseph Sarret, President & Chief Executive Officer, CohBar


Health and Safety

All attendees will be required to complete a health declaration prior to attending the event. As part of this, attendees must declare that they are either fully vaccinated and /or have completed a negative Lateral Flow Test or PCR Test within 48 hours of the event*.
For further information around Health and Safety onsite, please visit the FAQ page here.
*Please note, this is subject to change at any time without prior notice.


MitoGlobal
Listed under MitoGlobal Events.


Labels:






2022, MitoGlobal